Targeting Myeloid Chemotaxis to Reverse Prostate Cancer Therapy Resistance

Investigators showed that inhibition of myeloid chemotaxis could reduce tumor-elicited myeloid inflammation and reverse therapy resistance in a subset of metastatic CRPC patients.